Jubault V, Penfornis A, Schillo F, Hoen B, Izembart M, Timsit J, Kazatchkine M D, Gilquin J, Viard J P
Service d'Immunologie Clinique, Hôpital Necker, Paris, France.
J Clin Endocrinol Metab. 2000 Nov;85(11):4254-7. doi: 10.1210/jcem.85.11.6988.
We analyzed the kinetics of CD4 cells, human immunodeficiency virus (HIV) viral load, and autoantibodies in acquired immune deficiency syndrome patients with Graves' disease (GD) after immune restoration on highly active antiretroviral therapy (HAART; retrospective study). Five patients (median age, 41 yr) were diagnosed with GD after 20 (range, 14-22) months on HAART on the basis of clinical and biological hyperthyroidism, diffuse hyperfixation of thyroid scan, and the presence of anti-TSH receptor (anti-TSHR) antibodies (Ab). GD was diagnosed several months after the plasma HIV ribonucleic acid load became undetectable, when the CD4+ cell count had risen from 14 (range, 0-62) to 340 (range, 163-460) x 10(6) cells/L. Antithyroid peroxidase (anti-TPO) and anti-TSHRAb appeared 14 (range, 9-18) and 14 (range, 11-20) months after starting HAART and 12 (range, 6-15) and 11 (range, 9-17) months after the increase in CD4+ cells. In 3 patients, TPOAb preceded TSHRAb by 3-10 months. No other autoantibodies were detected. Thyroid antibodies were absent in a group of 55 HIV-1-positive patients with comparable response to HAART and no symptoms of hyperthyroidism (cross-sectional study). Thyroid-specific autoimmunity can occur upon immune restoration with HAART. Our observations suggest a relationship between thymus-dependent immune reconstitution after immunosuppression and autoimmunity and may provide insight into the pathophysiology of GD.
我们分析了接受高效抗逆转录病毒治疗(HAART;回顾性研究)后免疫重建的获得性免疫缺陷综合征合并格雷夫斯病(GD)患者的CD4细胞动力学、人类免疫缺陷病毒(HIV)病毒载量和自身抗体。5例患者(中位年龄41岁)在接受HAART治疗20个月(范围14 - 22个月)后,根据临床和生物学甲亢表现、甲状腺扫描弥漫性高度摄取以及抗促甲状腺激素受体(anti - TSHR)抗体(Ab)的存在被诊断为GD。GD在血浆HIV核糖核酸载量变得不可检测数月后被诊断出来,此时CD4 +细胞计数已从14(范围0 - 62)升至340(范围163 - 460)×10⁶细胞/L。抗甲状腺过氧化物酶(anti - TPO)和抗TSHRAb分别在开始HAART后14个月(范围9 - 18个月)和14个月(范围11 - 20个月)出现,在CD4 +细胞增加后12个月(范围6 - 15个月)和11个月(范围9 - 17个月)出现。在3例患者中,TPOAb比TSHRAb早出现3 - 10个月。未检测到其他自身抗体。在一组55例对HAART反应相当且无甲亢症状的HIV - 1阳性患者中未发现甲状腺抗体(横断面研究)。HAART免疫重建后可发生甲状腺特异性自身免疫。我们的观察结果提示免疫抑制后胸腺依赖性免疫重建与自身免疫之间的关系,并可能为GD的病理生理学提供见解。